Sun Pharma's ILUMYA gets USFDA approval for psoriatic arthritis treatment

The US FDA approval expands ILUMYA's use beyond plaque psoriasis, adding a new treatment option for adults with active psoriatic arthritis
Affected stocks
Neutral1 stockBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Sun Pharmaceutical Industries (SUNPHARMA).
- Category: Company.
Why it matters
A routine update for Sun Pharmaceutical Industries. Use the price and stock snapshot to gauge how the market is responding.













